Influence of omalizumab therapy on airway remodeling assessed with high-resolution computed tomography (HRCT) in severe allergic asthma patients by Przybyszowski, Marek et al.
PRACA ORYGINALNA
282
O IGINAL RESE RCH
www.journals.viamedica.pl
Address for correspondence: Marek Przybyszowski II Chair of Internal Medicine, Faculty of Medicine, Department of Pulmonology, Jagiellonian University Medical College,  
Skawińska 8, 31–066 Kraków, Poland, e-mail: mprzybyszowski@gmail.com
DOI: 10.5603/ARM.a2018.0046
Received: 17.10.2018
Copyright © 2018 PTChP
ISSN 2451–4934
Marek Przybyszowski1, Kinga Paciorek2, Weronika Zastrzeżyńska1, Agnieszka Gawlewicz-Mroczka1, 
Anna Trojan-Królikowska1, Anna Orłowska2, Jerzy Soja1, Wiesław Pawlik2, Krzysztof Sładek1
1II Chair of Internal Medicine, Faculty of Medicine, Department of Pulmonology, Jagiellonian University Medical College, Kraków, 
Poland
2Division of Radiology, Department of Allergology and Immunology, Kraków University Hospital, Kraków, Poland
Influence of omalizumab therapy on airway remodeling assessed 
with high-resolution computed tomography (HRCT) in severe 
allergic asthma patients
The authors declare no finacial disclosure
Abstract
Introduction: Airway remodeling is an important factor in persistent obstruction in severe asthma. High resolution computed 
tomography (HRCT) is an effective method of detecting changes in airway structure. Our aim was to use HRCT to assess changes 
in airway remodeling in patients with severe allergic asthma who are treated with omalizumab. 
Material and methods: In 12 patients with severe allergic asthma, HRCT was performed before and after treatment with oma-
lizumab. In selected bronchial airways, parameters were calculated: bronchial wall area (BA), also corrected for body surface 
area (BSA); percentage of wall area (WA%); and the ratio of luminal area to total bronchial area (Ai/Ao). Clinical response to 
treatment was assessed using an asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ), and number 
of exacerbations per year. Assessment included spirometry and blood eosinophilia. 
Results: Treatment resulted in significant improvement in ACQ (p = 0.035) and AQLQ (p = 0.001). We observed significant 
reduction in exacerbations per year (p = 0.002) and reduction of daily systemic steroid dose (p = 0.032). FEV1 and peripheral 
blood eospinophilia did not change (p = 0.846 and p = 0.221). Airway dimensions (Ai/Ao) of particular bronchi were consistent 
with the mean of the parameters calculated for all bronchi measured. Although we observed a significant decrease in WA (p = 
0.002) and WA/BSA (p = 0.002), WA% and Ai/Ao did not improve (p = 0.39 and p = 0.49). We found no correlations between 
changes in airways and changes in spirometry or clinical parameters. 
Conclusion: Despite clinical effectiveness of omalizumab, its effect on airway remodeling may be limited. 
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Introduction
Severe allergic asthma is characterized by 
chronic inflammatory process in the airways, 
triggered by exposure to allergens such as dust 
mites, mold, and animal dander. Immunoglobulin 
E (IgE) plays a central role in asthma, not only by 
inducing rapid bronchoconstriction and mucus 
hypersecretion through type I allergic reaction, 
but also by migration and activation of inflam-
matory cells (predominantly mast cells, Th2 
lymphocytes and eosinophils), leading to chronic 
inflammation in the airways [1]. This, in turn, 
leads to changes in bronchial structure, known 
as airway remodeling, which is characterized by 
reticular basement membrane (RBM) thickening, 
airway smooth-muscle hypertrophy, and mucus 
glands hyperplasia [2, 3].
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Omalizumab, a humanized monoclonal anti-
-IgE antibody, is a proven effective add-on therapy 
in treatment of severe allergic asthma, resulting 
in significant improvement in asthma control, 
quality of life, and reduction in exacerbations 
and use of systemic corticosteroids [4, 5]. Both 
experimental and clinical studies demonstrate 
the positive effect of biological treatment with 
anti-IgE on airway remodeling, expressed as 
RBM thickening or increased deposition of extra-
cellular matrix proteins in bronchial biopsies 
[3, 6, 7]. However, the necessity of performing 
bronchoscopy with a biopsy limits the utility of 
this method. Consequently, chest high resolution 
computed tomography (HRCT) has emerged as 
a useful non-invasive method of airway remode-
ling assessment in asthma [8].
 Our aim was to assess the effect of omalizu-
mab on clinical outcomes and airway remodeling 
in patients with severe allergic asthma, as measu-




We assessed clinical parameters and airway 
wall remodeling changes, measured with chest 
HRCT, in twelve patients with severe uncontro-
lled allergic asthma before and after biological 
treatment with omalizumab. Patients were qu-
alified for this biological treatment program with 
omalizumab based on Polish National Health 
Fund criteria [9]. 
All patients were diagnosed with severe 
asthma according to Global Initiative for Asthma 
(GINA) guidelines. Allergy to perennial allergens 
(dust mites, cat and dog dander) was confirmed 
with skin prick tests or a positive serum specific 
IgE test. Serum total IgE concentration between 
30 and 1500 IU/ml was required, as well as 
meeting at least three of the following criteria: 
uncontrolled asthma according to the Asthma 
Control Questionnaire (ACQ); Asthma Quality 
of Life Questionnaire (AQLQ) score < 5.0 points; 
three or more exacerbations in the preceding 12 
months requiring starting or increasing oral corti-
costeroid (OCS) dose; at least one hospitalization 
due to asthma exacerbation in the preceding 12 
months; life-threatening asthma exacerbation in 
the past; or persistent airway obstruction with 
forced expiratory volume (FEV1) < 60% of pre-
dicted value. Contraindications for omalizumab 
treatment included active smoking, pregnancy, 
breastfeeding, ongoing treatment with other biolo-
gical or immunosuppressive agents, and presence 
of comorbidities worsening asthma severity.
The dose of omalizumab was calculated on 
the basis of serum total IgE level and the patient’s 
weight. Omalizumab was administered subcuta-
neously every two or four weeks. The treatment 
lasted at least four months, after which patients 
were reevaluated. Clinical efficacy of the treat-
ment was assessed with ACQ, AQLQ, number of 
exacerbations, and OCS dose. Lack of significant 
improvement in asthma control (defined as a drop 
in ACQ result by 0.5 points, drop in number of 
asthma exacerbations, and lowering the OCS dose 
at least by four milligrams of methylprednisolone 
equivalent), resulted in termination of treatment. 
Improvement of at least two of the parameters 
allowed the therapy to continue.
All patients had chest HRCT before and after 
the therapy. As the treatment period differed for 
each patient, changes in airway dimensions, as 
measured by HRCT, were correlated with treat-
ment duration.
Clinical parameters, spirometry and blood 
eosinophilia
Prior to treatment, all relevant data related to 
asthma history were acquired, including asthma 
treatment, disease duration, reported allergies, 
and the number of severe exacerbations requiring 
systemic corticosteroids in the preceding 12 mon-
ths. Asthma control and quality of life were evalu-
ated with ACQ and AQLQ. The same information 
was collected after treatment and compared to 
the pre-treatment period. Allergy to perennial 
allergens was confirmed with allergy skin-prick 
tests or specific IgE testing. All patients had ba-
sic spirometry (MasterScreen, Jaeger, Wurzburg, 
Germany). Blood samples for peripheral blood 
eosinophilia and total IgE level were obtained 
before and after omalizumab treatment. 
Lung imaging
In all study patients, thin collimation MDCT 
acquisition over the entire lungs at full suspen-
ded inspiration and reconstruction of contiguous 
0.5 mm high resolution axial images was per-
formed, both before and after treatment in the 
exacerbation-free period. CTs were performed 
with Toshiba Aquillon 64 tomograph (Toshiba 
Medical, Tokyo, Japan) with the following pa-
rameters: 120 kV, 200mA, 0.5 mm collimation. 
Data were reconstructed with a 0.5 mm interval, 
512 × 512 matrix, and images were displayed on 
a window width of 1500 Hounsfield units (HU) 
and a window level of –500 HU. Obtained images 
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were transferred to a workstation and analyzed 
by a qualified radiologist who was blinded to the 
patient’s clinical status. Using a semi-automated 
method and dedicated software (3D Slicer Airway 
Inspector, version 4.8, www.airwayinspector.acil-
bwh.org), a quantitative analysis of airway remod-
eling was performed, as described elsewhere [10]. 
First, we identified bronchi, which prom-
ised the most accurate measurement of airway 
diameters. Segmental, subsegmental and sub-sub-
segmental (3rd, 4th and 5th generation) bronchi 
to first and tenth segments of the right and left 
lung were chosen for further measurements. On 
cross-sectional scans, the place of measurement 
was selected by the radiologist, then software 
automatically calculated airway diameters. The 
following parameters were measured in each 
bronchus: wall area (WA); WA corrected for 
body surface area (WA/BSA); and the luminal 
area to outer airway area ratio (Ai/Ao). Finally, 
in each patient, 8 to 15 bronchi were analyzed. 
We selected one bronchus from each investigated 
generation, which was reliably visualised in each 
patient: the tenth left basal segment (L10); first 
right apical subsegment (R1.a); and the first right 
apical sub-subsegment (R1.a.1). In addition, the 
mean value of Ai/Ao in all measured bronchi and 
the sum of WA and WA/BSA of the three selected 
bronchi were calculated. 
Inter-observer reproducibility was assessed 
by having another radiologist independently 
analyze the same parametrs in R1.a in five ran-
domly selected patients. The mean results were 
compared using t-test.
Statistical analysis
All data were analyzed using Statistica soft-
ware (ver. 12, StatSoft). Values were expressed 
as means with standard deviations (SD — in 
parentheses). For comparisons of changes in clin-
ical parameters, pulmonary function tests, inter- 
-observer mesurement reproducibility and airway 
diameters pre- and post- treatment, the t-test for 
related samples was used. Correlations between 
changes in airway diameters, clinical parame-
ters and lung function for normal distributions 
were made using the Pearson’s linear correlation 
coefficient. The significance of the differences 
between alternative methods of airway remode-
ling assessment (measurement of Ai/Ao in single 
bronchus, three selected bronchi or the mean of 
all measured bronchi as well as pre- and post- 
-treatment changes of those parameters) was 
verified by univariate analysis of variance (ANO-
VA). In case of significant difference, a post-hoc 
Scheffe test was used successively to identify spe-
cific comparison pairs differing from each other. 
A p value = 0.05 was considered significant. 
Results
Characteristics of study subjects are pre-
sented in Table 1. All patients met the inclusion 
criteria of Polish National Health Fund program. 
None of the patients actively smoked. After four 
months of biological treatment, one patient was 
disqualified from further therapy due to poor re-
sponse. Eleven patients were evaluated as good 
responders and continued the treatment for dif-
ferent periods of time. The mean treatment period 
in the studied group was 30.8 months (± 16.1), 
and the mean dose of omalizumab was 475 mg 
(± 277.7) for four weeks.
Clinical parameters
We observed significant improvement in 
asthma control after treatment with omalizumab. 
The mean ACQ result dropped from 3.14 to 2.4 
points (p = 0.035). At the same time, significant 
improvement in quality of life was observed, 
with the mean AQLQ score rising from 3.54 to 
4.68 points (p = 0.001). Mean exacerbation rate 
declined significantly from 5.5 to 1.5 per year 
(p = 0.002). During therapy, the mean daily 
OCS dose was significantly reduced from 14.67 
Table 1. Characteristics of study subjects
Parameter All (n = 12)
Female, n (%) 10 (83.33)
Age (yrs), mean (SD) 47.9 (8.58)
BMI (kg/m2), mean (SD) 25.52 (4.84)
BSA (m2), mean (SD) 1.83 (0.26)
Asthma duration (yrs), mean (SD) 29.42 (16.0)
Treatment duration (months), mean (SD) 30.75 (16.09)
FEV1 % predicted, mean (SD) 73.07 (18.43)
FEV1%/FVC after bronchodilator, mean (SD) 63.77 (9.88)
Fixed obstruction, n (%) 10 (83.33)
OCS users, n (%) 12 (100)
OCS (mg/day), mean (SD) 14.67 (8.23)
ICS high dosea, n (%) 12 (100)
Omalizumab dose (mg/4 weeks), mean (SD) 425 (277.57)
IgE (IU/uL), mean (SD) 228.69 (134.08)
Peripheral blood eosinophilia (cells/uL),  
mean (SD)
202.5 (127.36)
adefined as daily dose of ≥ 1000 ug of fluticasone equivalent
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Table 2. Comparison of clinical parameters, spirometry and blood eosinophilia before and after treatment with omalizumab
Parameter Before treatment After treatment p
ACQ, mean (SD) 3.14 (0.46) 2.4 (1.06) 0.035
AQLQ, mean (SD) 3.54 (0.77) 4.68 (0.65) 0.001
Exacerbations per 12 months, mean (SD) 5.5 (2.94) 1.5 (1.78) 0.002
FEV1 % predicted, mean (SD) 73.07 (18.43) 72.18 (19.22) 0.846
FEV1%/FVC after bronchodilator, mean (SD) 63.77 (9.88) 67.19 (8.62) 0.160
OCS (mg/day), mean (SD) 14.67 (8.23) 10.50 (11.06) 0.032
Peripheral blood eosinophilia (cells/uL), mean (SD) 202.5 (127.36) 261.67 (182.60) 0.221
milligrams of methylprednisolone equivalent to 
10.5 milligrams (p = 0.032), while the mean dose 
of inhaled corticosteroids (ICS) did not change 
significantly. 
Spirometry
Mean FEV1 did not change significantly after 
treatment (p = 0.848). Mean FEV1/FVC impro-
ved insignificantly from 63.77% to 67.19% (p = 
0.160). However, in three patients, we observed 
an increase in the FEV1/FVC ratio, exceeding 70%, 
as compared to the pre-treatment period. 
Blood eosinophilia
We observed an insignificant increase in 
peripheral blood eosinophilia from 202.5/ul to 
261.57/ul following treatment (p = 0.221). Com-
parisons between pre- and post-treatment clinical 
parameters, lung function tests and eosinophilia 
are presented in Table 2. 
Airway remodeling assessed with HRCT
The total WA and WA/BSA of three selected 
bronchi were significantly reduced in comparison 
to the pre-treatment period: 124.53 mm2 versus 
105.40 mm2, [p = 0.002], and 68.26 mm2/m2 
versus 58.16 mm2/m2, [p = 0.002] respectively. 
No significant changes were observed in Ai/Ao 
of three selected bronchi, and in Ai/Ao of all 
bronchi measured (0.36 versus 0.35 [p = 0.565], 
and 0.35 versus 0.34 [p = 0.491], respectively) 
(Fig. 1). Changes in WA and WA/BSA of selected 
bronchi did not correlate with changes in FEV1, 
ACQ, AQLQ, exacerbation rate, treatment time or 
asthma duration (Table 3). Selected correlations 
are shown in Figure 2. 
In the univariate ANOVA and the post-hoc 
Scheffe test, mean Ai/Ao of all measured bronchi 
was not statistically different from Ai/Ao of indi-
vidual bronchi (Table 4). No significant differenc-
es were observed between pre- and post-treatment 
changes of Ai/Ao of individual bronchi, mean 
Ai/Ao of three selected bronchi, or all bronchi 
measured (p = 0.774).
Inter-observer reproducibility was satisfac-
tory. No significant differences were observed in 
mean WA (34.11 mm2 vs 31.98 mm2 [p = 0.428]), 
WA/BSA (20.29 mm2/m2 vs 19.22 mm2/m2 [p = 
0.481], WA% (62.65% vs 61.68% [p = 0.308]) 
and Ai/Ao (0.393 vs 0.383 [p = 0.522]) of R1a 
measured by two independent radiologists.
Discussion
Results of our study show, that in real-life 
conditions, omalizumab is an effective add-on 
therapy for patients with severe allergic asthma, 
which remains uncontrolled despite intensive 
treatment. We confirmed that biological treatment 
with omalizumab significantly improves asthma 
control, asthma-related quality of life and lowers 
exacerbation rate. In addition, the treatment allo-
wed for significant reduction in daily OCS dose in 
the studied group. Our findings align with results 
of previous studies on this topic [5, 11].
However, despite significant improvement in 
clinical outcomes, treatment with omalizumab 
only partially influenced airway wall remodeling. 
Decrease in WA and WA/BSA, while significant, 
was not associated with improvement in the 
airway lumen area to bronchial wall area ratio 
(Ai/Ao). FEV1 and peripheral blood eosinophilia 
remained unchanged. Moreover, we did not ob-
serve significant correlations between changes in 
bronchial wall area and FEV1. 
Our study is one of the few published studies 
assessing the effect of omalizumab therapy on 
airway remodeling assessed with chest HRCT. 
Hoshino et al. demonstrated a  spectacular de-
crease in bronchial wall area with increase in 
luminal area during omalizumab treatment, 
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Figure 1. Changes in bronchial wall area after biolgical treatment with omalizumab
Table 3. Correlations between changes in airway dimensions and clinical parameters
Parameter D FEV1 D FEV1/
FVC
D ACQ D AQLQ D number of exacer-
bations/12 months
asthma duration treatment duration
D WA of selected bronchi
R 0.127 0.501 –0.006 –0.363 0.566 0.087 –0.302
p-value 0.695 0.097 0.986 0.247 0.055 0.788 0.340
D WA/BSA of selected bronchi
R 0.092 0.469 –0.013 –0.380 0.555 0.101 –0.193
p-value 0.775 0.124 0.969 0.223 0.061 0.756 0.547
while airway remodeling parameters in patients 
with asthma treated with ICS only remained 
unchanged. He also observed a significant incre-
ase in FEV1 and reduction of eosinophil count 
in induced sputum among biologically treated 
patients [12]. Similarly, Tajiri et al. [13] observed 
improvement in WA%, which also correlated with 
decrease in sputum eosinophils and the level of 
exhaled nitric oxide. 
Findings in these studies are not consistent 
with our results, likely due to several noteworthy 
differences between them and our study. First, 
mean duration of asthma (30 years) was almost 
twice as long in our study as compared to Hoshi-
no’s work (16.3 years) and Tajiri’s (16.2 years). 
As proven in previous studies, airway remode-
ling severity is proportional to disease duration 
[8, 14, 15]. Observations by Boulet et al. [16] 
indicate that remodeling occurs at early stages of 
asthma, even with short history of symptomatic 
disease. Additionally, changes in airway struc-
ture are not fully reversible with ICS treatment. 
Marek Przybyszowski et al., Omalizumab and airway remodeling in asthma
287www.journals.viamedica.pl
Figure 2. Selected correlations between changes in airway dimensions and clinical parameters
Table 4. Comparison of pre-treatment airway remodeling parameters with checking for significant differences between them
Post-hocTest Scheffe
(p-value)
Mean Ai/Ao of 
three selected 
bronchi
Mean Ai/Ao of 
all bronchi
Ao/Ai L10 Ao/Ai R1a Ao/Ai R1.a.1
Mean Ai/Ao of three selected bronchi — 0.995 0.225 0.960 0.048
Mean Ai/Ao of all bronchi 0.995 — 0.100 0.824 0.122
Ao/Ai L10 0.225 0.100 — 0.616 0.000
Ao/Ai R1a 0.960 0.824 0.616 — 0.007
Ao/Ai R1.a.1 0.048 0.122 0.000 0.007 —
Therefore, the effect of anti-inflammatory tre-
atment on airways profoundly remodeled by 
a long-term inflammatory process is likely to be 
limited. Second, 10 of the 12 studied patients had 
persistent obstruction, confirmed with a FEV1/ 
/FVC ratio below 70% after use of a bronchodi-
lator. As previously shown, the degree of airway 
obstruction is linked with increase in airway 
thickness, especially in distal bronchi [8, 17, 18]. 
Significant airway thickening was observed in 
both proximal and distal bronchi among patients 
with asthma who have fixed obstruction, despite 
anti-inflammatory treatment with inhaled or sys-
temic steroids [19]. Although some studies show 
positive effects of anti-inflammatory treatment 
with ICS or ICS+long acting beta agonists on 
airway remodeling parameters in chest HRCT 
[20, 21], they were performed on patients with 
mild to moderate asthma who were steroid-naïve. 
Finally, our studied group consisted exclusively 
of patients with long-term severe asthma with 
persistent obstruction and uncontrolled disease 
despite long-term treatment with high doses of 
ICS or OCS. As proven, airway remodeling advan-
cement is closely linked to disease severity [22]. 
Therefore, we conclude that those factors may be 
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Figure 3. Changes of Ai/Ao in selected patient’s bronchi measured with chest HRCT before and after treatment with omalizumab
responsible for only partial response to treatment 
in terms of changes in airway remodeling.
In many studies, different parameters of 
airway remodeling measured in chest HRCT 
were analyzed. Some authors indicate absolute 
parameters such as WA as the most accurate, 
since relative parameters (e.g. WA%, Ai/Ao) may 
be dependent on lung volume, bronchial dilation 
and presence of bronchiectases [8, 23]. However, 
thickness of the bronchi is affected by bronchial 
size and does not inform about the inside of the 
bronchus. A more precise determination of airway 
condition might come from evaluating relative 
parameters — bronchial thickness and lumen 
diameter — as they reflect airway narrowing. 
The studies also vary in selection of bronchi for 
airway measurements. In our study, we measured 
between 8 to 15 bronchi in each patient. In all 
of them, we observed very consistent changes in 
remodeling parameters (Fig. 3). The mean Ai/Ao 
of all bronchi was not significantly different from 
Ai/Ao of particular bronchi, therefore, this could 
be reflective of airway dimensions in a patient. In 
our opinion, lack of improvement in the ratio of 
lumen area to bronchial area (Ai/Ao) corresponds 
with unchanged FEV1 and features of fixed obs-
truction within the studied group. 
In four patients, we observed marked improve-
ment of all remodeling parameters. The pre- to 
post-treatment changes in HRCT scans of patients 
with improvement of airway diameters, as well as 
of patients without improvement, are shown on 
Figure 4. In those patients, however, lung func-
tion, expressed as FEV1, did not improve. It has 
to be taken into consideration that the influence 
of omalizumab on small airways in our patients 
is unknown. Previous research by Little et al. [24] 
demonstrated that the degree of remodeling corre-
sponded with FEF25-75 rather than with FEV1. This 
may reflect significant impact of the small airways 
remodeling on lung function. Similar results were 
provided by Hoshino, who observed stronger cor-
relations between lung function and remodeling in 
distal rather than in proximal airways [17]. Unfor-
tunately, because of our small patient sample, we 
were unable to investigate significant differences 
between patients who improved in HRCT and those 
who did not respond well to therapy.
We observed no significant change in pe-
ripheral blood eosinophilia during treatment. 
Several studies analyzed the effect of IgE on 
eosinophils. As shown previously, IgE contributes 
to airway inflammation not only through mast 
cell degranulation and direct influence on the 
airways, but also through eosinophil activation 
[25, 26]. Anti-IgE treatment was shown to be 
particularly effective in patients with asthma 
with high blood eosinophil count [27]. Djukano-
vic et al. [28] found that omalizumab decreased 
eosinophilic infiltrates in bronchial mucosa. On 
the other hand, in the recent STELLAIR study, 
efficacy of anti-IgE therapy was similar in patients 
with high and low blood eosinophilia, and initial 
eosinophil count was not predictive of treatment 
outcome [29]. Discrepancies between studies 
suggest that the relationship between IgE, eosi-
nophilic inflammation and airway remodeling 
requires further investigation.
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Figure 4. Chest CT scans of two patients with marked improvement in airway remodelling (A and B) and two patients without improvement (C and D) 
— comparison before and after the treatment
Our study has some limitations. First is the 
small number of patients with asthma, which did 
not allow us to investigate subgroups of patients 
with various airway remodeling changes. This 
may have biased our statistical analysis. Second, 
biological treatment duration varied significantly 
between our patients, due to individual patient’s 
decisions and disqualification of one patient 
because of lack of response to therapy. However, 
our results indicate that treatment duration did 
not correlate with observed bronchial wall area 
changes. It may reflect the fact that remodeling 
in patients with long term severe asthma is an 
advanced process, [15] which cannot be fully 
reversed with either short or long term biological 
treatment. Such conclusion is also supported by 
the fact that we did not observe improvement 
in spirometry. Third, our group consisted exc-
lusively of patients with severe uncontrolled 
asthma with long-standing disease, frequent 
exacerbations, and high ICS and OCS intake. 
These were the only patients who could qualify 
for omalizumab treatment in accordance with 
the requirements of the National Health Fund. 
However, patients with severe allergic asthma are 
a heterogeneous group [30], and therefore, large 
studies on severity-stratified patients with asthma 
are needed. Despite those limitations, we have 
thoroughly evaluated the influence of omalizu-
mab treatment on clinical parameters and airway 
remodeling among patients with long-term severe 
allergic asthma in a single tertiary medical center.
Conclusions
The addition of omalizumab to standard 
asthma treatment improved asthma control, 
asthma-related quality of life, OCS intake, and 
exacerbation frequency in patients with long-term 
severe allergic asthma. However, the influence of 
biological treatment on airway remodeling was 
only partial and without effect on spirometry and 
blood eosinophilia. The influence of biological 
treatment on airway remodeling in different gro-
ups of patients with asthma needs further studies. 
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